ciprofibrate has been researched along with tyloxapol in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Borensztajn, J; Davidson, NO; Fu, T; Mukhopadhyay, D | 1 |
1 other study(ies) available for ciprofibrate and tyloxapol
Article | Year |
---|---|
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; Cytoplasm; Female; Fibric Acids; Intestinal Mucosa; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peroxisome Proliferators; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA; RNA Editing; RNA, Messenger; Time Factors; Transcription Factors; Triglycerides | 2004 |